EUVIMEDEUVIMED entdecken
Crossref

Results of the RIST-rNB-2011 trial for relapsed or refractory neuroblastoma

S Corbacioglu

Klinische Pädiatrie · 01.05.2024 · 236 (03) · 202-203

DOI: 10.1055/s-0044-1786565 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Klinische Pädiatrie, erschienen am 01.05.2024. Verfasst von S Corbacioglu.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Relapsed or refractory neuroblastoma (r/rNB) are associated with a dismal outcome. RIST-rNB-2011, an open label randomised phase II trial (NCT01467986) compared RIST (rapamycin, dasatinib, irinotecan, temozolomide) with I/T alone. 129 patients with relapsed high-risk and refractory NB were randomly assigned to RIST or I/T, stratified by MYCN. Primary endpoint was PFS. 99 (80%) were relapsed and 24 (19%) refractory NB patients. At a median follow-up of 72 months the median PFS was 11 (95%-CI 7-17) months in RIST and 5 (2-8) months in CA (HR: 0·62 [95%-CI: 0·42, 0·92], p=0·019). Median PFS with RIST in MYCN-A patients was 6 (95%-CI 4-24) months versus 2 (2-5) months in the CA (HR: 0.45 (0·24, 0·84), p=0·012). PFS in the MYCN-A subgroup for RIST versus CA was 33% versus 8% at 2 years. Median OS with RIST in MYCN-A patients was 11 (95%-CI 7-26) months versus 6·5 (95%-CI 3-15) months in the CA (HR: 0·51 (95%-CI: 0·27, 0·96), p=0·037). No difference in outcome was observed in the MYCN non-amplified (MYCN-NA) patients. Conclusion: RIST demonstrated a significant and sustained anti-tumour activity, selectively in the highest-risk group of MYCN-A patients with r/rNB. Publication History Article published online: 10 May 2024 © 2024. Thieme. All rights reserved. Georg Thieme Verlag KG Rüdigerstraße 14, 70469 Stuttgart, Germany

Zitieren

APA

Corbacioglu, S. (2024). Results of the RIST-rNB-2011 trial for relapsed or refractory neuroblastoma. Klinische Pädiatrie, 236(03), 202-203. https://doi.org/10.1055/s-0044-1786565

Vancouver

Corbacioglu S. Results of the RIST-rNB-2011 trial for relapsed or refractory neuroblastoma. Klinische Pädiatrie. 2024;236(03):202-203. doi:10.1055/s-0044-1786565

BibTeX
@article{Corbacioglu2024,
  author = {Corbacioglu, S},
  title = {Results of the RIST-rNB-2011 trial for relapsed or refractory neuroblastoma},
  journal = {Klinische Pädiatrie},
  year = {2024},
  volume = {236},
  number = {03},
  pages = {202--203},
  doi = {10.1055/s-0044-1786565}
}
Kostenlos starten →